国际输血及血液学杂志
國際輸血及血液學雜誌
국제수혈급혈액학잡지
INTERNATIONAL JOURNAL OF BLOOD TRANSFUSION AND HEMATOLOGY
2013年
6期
483-485
,共3页
抗肿瘤联合化疗方案%白血病,髓样,急性%复发%预后
抗腫瘤聯閤化療方案%白血病,髓樣,急性%複髮%預後
항종류연합화료방안%백혈병,수양,급성%복발%예후
antineoplastic combined chemotherapy protocols%leukemia,myeloid,acute%recurrence%prognosis
目的 探讨急性髓系白血病(AML)高龄患者采用CAG[阿糖胞苷(Ara-C)+阿克那霉素(Acla)+粒细胞集落刺激因子(G-CSF)]方案诱导缓解化疗的临床疗效及预后.方法 选择2008年1月至2012年1月,本院收治的80例AML高龄患者作为研究对象.根据住院号将其随机分为两组:接受CAG诱导缓解化疗方案治疗者纳入CAG组(n=40),接受FA[氟达拉滨(Flud)+ Ara-C]方案治疗者纳入FA组(n=40).两组患者在性别、年龄、法国-美国-英国协作组(FAB)分型、骨髓象特征等一般资料方面比较,差异无统计学意义(P＞0.05)(本研究遵循的程序符合湖北省天门市第一人民医院人体试验委员会所制定的伦理学标准,得到该伦理会批准,分组征得受试对象本人的知情同意,并与之签订临床研究知情同意书).随访18个月,观察两组患者的缓解率和不良反应发生情况,分别对治疗疗效、复发及预后等情况进行分析比较.结果 CAG组的总缓解率显著高于FA组,两组相比差异有统计学意义(P＜0.05);CAG组患者感染、骨髓抑制和肝功能异常率显著低于FA组,两组相比差异有统计学意义(P＜0.05);随访12和18个月时的复发率,CAG组显著低于FA组,两组相比差异有统计学意义(P＜0.05).结论 对AML高龄患者采用CAG诱导缓解化疗方案治疗可以有效的提高临床疗效,不良反应小并且复发率低,预后较好.
目的 探討急性髓繫白血病(AML)高齡患者採用CAG[阿糖胞苷(Ara-C)+阿剋那黴素(Acla)+粒細胞集落刺激因子(G-CSF)]方案誘導緩解化療的臨床療效及預後.方法 選擇2008年1月至2012年1月,本院收治的80例AML高齡患者作為研究對象.根據住院號將其隨機分為兩組:接受CAG誘導緩解化療方案治療者納入CAG組(n=40),接受FA[氟達拉濱(Flud)+ Ara-C]方案治療者納入FA組(n=40).兩組患者在性彆、年齡、法國-美國-英國協作組(FAB)分型、骨髓象特徵等一般資料方麵比較,差異無統計學意義(P＞0.05)(本研究遵循的程序符閤湖北省天門市第一人民醫院人體試驗委員會所製定的倫理學標準,得到該倫理會批準,分組徵得受試對象本人的知情同意,併與之籤訂臨床研究知情同意書).隨訪18箇月,觀察兩組患者的緩解率和不良反應髮生情況,分彆對治療療效、複髮及預後等情況進行分析比較.結果 CAG組的總緩解率顯著高于FA組,兩組相比差異有統計學意義(P＜0.05);CAG組患者感染、骨髓抑製和肝功能異常率顯著低于FA組,兩組相比差異有統計學意義(P＜0.05);隨訪12和18箇月時的複髮率,CAG組顯著低于FA組,兩組相比差異有統計學意義(P＜0.05).結論 對AML高齡患者採用CAG誘導緩解化療方案治療可以有效的提高臨床療效,不良反應小併且複髮率低,預後較好.
목적 탐토급성수계백혈병(AML)고령환자채용CAG[아당포감(Ara-C)+아극나매소(Acla)+립세포집락자격인자(G-CSF)]방안유도완해화료적림상료효급예후.방법 선택2008년1월지2012년1월,본원수치적80례AML고령환자작위연구대상.근거주원호장기수궤분위량조:접수CAG유도완해화료방안치료자납입CAG조(n=40),접수FA[불체랍빈(Flud)+ Ara-C]방안치료자납입FA조(n=40).량조환자재성별、년령、법국-미국-영국협작조(FAB)분형、골수상특정등일반자료방면비교,차이무통계학의의(P＞0.05)(본연구준순적정서부합호북성천문시제일인민의원인체시험위원회소제정적윤리학표준,득도해윤리회비준,분조정득수시대상본인적지정동의,병여지첨정림상연구지정동의서).수방18개월,관찰량조환자적완해솔화불량반응발생정황,분별대치료료효、복발급예후등정황진행분석비교.결과 CAG조적총완해솔현저고우FA조,량조상비차이유통계학의의(P＜0.05);CAG조환자감염、골수억제화간공능이상솔현저저우FA조,량조상비차이유통계학의의(P＜0.05);수방12화18개월시적복발솔,CAG조현저저우FA조,량조상비차이유통계학의의(P＜0.05).결론 대AML고령환자채용CAG유도완해화료방안치료가이유효적제고림상료효,불량반응소병차복발솔저,예후교호.
Objective To explore the efficacy and prognosis of acute myeloid leukemia (AML) patients with CAG [cytarabine (Ara-C)+ ake kanamycin (Acla)+ granulocyte colony-stimulating factor (GCSF)] for remission induction chemotherapy.Methods From January 2008 to January 2012,80 AML patients in our hospital were selected as the research objects.According to the number of hospitalized,patients were randomly divided into two groups:received CAG chemotherapy regimen as the CAG group (n=40),and FA [fludarabine (Flud) + Ara-C] treatment were included in FA group (n=40).Compared two groups in gender,age,France-America-Britain(FAB) type,and bone marrow features such as general data,were no significant difference (P＞0.05) (The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Tianmen First People's Hospital.Informed consent was obtained from all participants).After 18 months time follow-up,two groups were observed in patients with ease the occurrence rate and adverse reaction,respectively on the curative effect,recurrence and prognosis analysis.Results The total remission rate in CAG group was higher than that in FA group,the difference was statistically significant (P＜0.05); patients,infection,inhibition and liver function of bone marrow abnormality rates in group CAG were lower than those in FA group,the differences were statistically significant (P＜0.05).Follow-up of 12 and 18 months,recurrence rates in CAG group were lower than those in FA group,the differences were statistically significant (P＜0.05).Conclusions AML patients with CAG remission induction chemotherapy could effectively improve the clinical efficacy,adverse reaction,with lower recurrence rate and better prognosis.
